Sage Journals: Discover world-class research

Abstract

Introduction

Venetoclax is a selective inhibitor of BCL2. While its combination with hypomethylating agents (HMAs) is associated with manageable side effects, thyroid dysfunction has not been previously reported.

Case Report

We present the case of a 62-year-old female with relapsed/refractory AML who was treated with azacitidine and venetoclax. Within a month, she developed hypothyroidism with elevated TSH (42.86 µIU/mL) and low FT4 (0.34 ng/dL). Baseline thyroid function tests were normal.

Management & Outcome

Ultrasonography showed a diffusely enlarged thyroid gland, and thyroid autoantibodies were negative, ruling out autoimmune thyroiditis.Thyroid hormone replacement therapy was initiated, normalizing thyroid function, while venetoclax was continued due to its efficacy.

Discussion

This case highlights a rare, non-autoimmune thyroid dysfunction associated with venetoclax. The absence of autoantibodies suggests a mechanism unrelated to autoimmunity, emphasizing the need for thyroid monitoring during venetoclax therapy.

Keywords

Hypothyroidism venetoclax leukemia

Get full access to this article

View all access options for this article.

References

Campos

EDV

Pinto

. Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematol Transfus Cell Ther 2019; 41: 169–177.

DiNardo

Pratz

Letai

, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018; 19: 216–228.

3. Venetoclax with Azacitidine Drains Fuel from AML Stem Cells Daisuke Nakada1, * 1Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.

DiNardo

Pratz

Pullarkat

, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019; 133: 7–17.

Jannina

Penelb

Ladsousa

, et al. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit. Rev. Oncol. Hematol. 2019; 141: 23–35.

Arora

Scholar

. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther 2005; 315: 971–979.

Brahmer

Reckamp

Baas

, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med 2015; 373: 123–135.

Taylor

Albrecht

Scholz

, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol 2018; 14: 301–316.

Venotoclax associated hypothyroidism in a patient with acute myeloid leukemia